Our convalescent plasma experiences in COVID-19 patients hospitalized in the intensive care unit

Authors : Bülent Barış GÜVEN, Tuna ERTÜRK, Egemen YILDIZ, Esra DURMAYÜKSEL, Aysin ERSOY, Alpaslan TANOĞLU

Pages : 600-606

Doi:10.32322/jhsm.1068864

View : 26 | Download : 10

Publication Date : 2022-03-15

Article Type : Research Paper

Abstract :Objective: Despite vaccine and drug studies, convalescent plasma insert ignore into journalissuearticles values(CP); therapy remains an alternative treatment for coronavirus disease 2019 insert ignore into journalissuearticles values(COVID-19);. In this study, we aimed to reveal the efficacy of CP therapy on mortality and the factors affecting it for the patients diagnosed with COVID-19 and acute respiratory distress syndrome insert ignore into journalissuearticles values(ARDS); which were followed in our intensive care unit insert ignore into journalissuearticles values(ICU);. Material and Method: The data insert ignore into journalissuearticles values(demographic characteristics, the amount of CP used, PaO2/FiO2, leukocyte, neutrophil, lymphocyte, D-Dimer, C-reactive protein insert ignore into journalissuearticles values(CRP);, procalcitonin, ferritin values, and the clinical findings); of the patients who were hospitalized in the ICU with the diagnosis of COVID-19 and received CP treatment between 20 March and 20 October 2020 were analyzed retrospectively. Data of deceased patients insert ignore into journalissuearticles values(n=29); and survivors insert ignore into journalissuearticles values(n=50); were compared with each other and logistic regression analysis was performed to investigate the relationship with mortality. Results: 79 patients who received 166 units of CP therapy after a mean of 13.45±3.6 days symptom onset, were identified. 96.2% of the patients had at least one concomitant disease. Mortality was observed in 29 insert ignore into journalissuearticles values(36.7%); of the patients. Mortality insert ignore into journalissuearticles values(5.1%); was less common in those receiving CP therapy within the first 14 days after the onset of symptoms. Patient age insert ignore into journalissuearticles values(p=0.041);, neutrophil/lymphocyte ratio insert ignore into journalissuearticles values(p=0.004);, CRP values insert ignore into journalissuearticles values(p=0.002);, the number of comorbidities insert ignore into journalissuearticles values(p<0.001);, PaO2/FiO2 ratio before CP insert ignore into journalissuearticles values(p=0.005);, and the period when CP was first infused from symptom onset insert ignore into journalissuearticles values(p<0.001); had a statistically significant effect on mortality. Conclusion: CP can be safely used to treat COVID-19. However, its positive effect is less observed in patients with the advanced stage of the disease, progressive deterioration of oxygenation, and a high number of comorbidities. For this reason, starting CP treatment at an early stage may increase its effectiveness.
Keywords : Convalescent immune, plasma, COVID 19, Intensive care unit, SARS Cov 2